Abivax is a French listed, late-stage clinical biotech company mobilizing the body’s natural immune system machinery to treat patients with inflammatory diseases, viral infections and cancer

Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis (UC), Crohn’s disease (CD), rheumatoid arthritis (RA), and other inflammatory diseases, and liver cancer

Capital raise proceeds will be mainly used for the continuation of the clinical programs of its lead product ABX 464 (obefazimod) and notably for further advancing the global phase 3 clinical study program in ulcerative colitis; financing of R&D, working capital and other general purposes of the Company; redemption of existing indebtedness

About Abivax

Abivax, a phase 3 clinical stage biotechnology company, is developing novel therapies that modulate the body’s natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, obefazimod (ABX464) to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Discover Abivax

Olivier Garnier

Investment Banking

Olivier Garnier photo

Clifford Siegel

Investment Banking

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Hervé Ronin

Investment Banking

Hervé Ronin photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Jérôme Guyot

Equity Capital Markets

Will Jungman

Investment Banking

Théodore de Charsonville

Equity Capital Markets

Théodore De Charsonville photo

Hugo Fischer

Equity Capital Markets

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }